½ÃÀ庸°í¼­
»óǰÄÚµå
1677842

Á¤¸ÆÇ÷Àü »öÀüÁõ Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : Á¦Ç°º°, ÀûÀÀ Áúȯº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)

Venous Thromboembolism Treatment Market Size, Share, and Growth Analysis, By Product, By Disease Indication, By End User, By Region - Industry Forecast 2025-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 219 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Á¤¸ÆÇ÷Àü »öÀüÁõ Ä¡·á ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 22¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â 23¾ï 1,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â 34¾ï 1,000¸¸ ´Þ·¯·Î ¼ºÀåÇϸç, ¿¹Ãø ±â°£(2025-2032³â)ÀÇ CAGRÀº 5.0%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

Á¤¸ÆÇ÷Àü»öÀüÁõ(VTE) Ä¡·á ½ÃÀåÀº Æó»öÀüÁõ ¹× ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ°ú °°Àº ½É°¢ÇÑ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ´Â Á¤¸Æ³» Ç÷Àü Çü¼ºÀ¸·Î Ư¡Áö¾îÁö´Â ½É°¢ÇÑ ¼¼°è °Ç°­ ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â ÁÂ½Ä »ýȰ½À°ü, °í·ÉÈ­, ¼ö¼ú°ú °ü·ÃµÈ VTEÀÇ À¯º´·ü Áõ°¡, È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. Ç×ÀÀ°í ¿ä¹ý, ƯÈ÷ Á÷Á¢ °æ±¸¿ë Ç×ÀÀ°íÁ¦(DOAC)¿Í ÁÖ»çÁ¦ÀÇ ¹ßÀüÀº ÃâÇ÷ À§ÇèÀ» ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. À§Çè ¿äÀο¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í Á¶±â Áø´ÜÀÇ Á߿伺ÀÌ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¸ÂÃã Ä¡·á Á¢±Ù¹ýÀÇ Çʿ伺°ú ȯÀÚÀÇ ¼øÀÀµµ¶ó´Â °úÁ¦¿¡µµ ºÒ±¸Çϰí VTE Ä¡·á ½ÃÀåÀº »ý¸íÀ» ±¸ÇÏ´Â ÁßÀ縦 Á¦°øÇÏ´Â µ¥ ÀÖÀ¸¸ç, ÇʼöÀûÀÎ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

¼­·Ð

  • Á¶»çÀÇ ¸ñÀû
  • Á¶»ç ¹üÀ§
  • Á¤ÀÇ

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀåÀÇ ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ

°³¿ä

  • ¼¼°è ½ÃÀå Àü¸Á
  • °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀΰú ±âȸ
    • ¾ïÁ¦¿äÀΰú °úÁ¦
  • PorterÀÇ »ê¾÷ ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • ÁÖ¿ä ¼º°ø ¿äÀÎ
  • °æÀïÀÇ Á¤µµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå ¿¡ÄڽýºÅÛ
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2024³â)
  • PESTEL ºÐ¼®
  • °Å½Ã°æÁ¦ ÁöÇ¥
  • ¹ë·ùüÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®

Á¤¸ÆÇ÷Àü »öÀüÁõ Ä¡·á ½ÃÀå ±Ô¸ð : Á¦Ç°º° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ºñºÎ¹®Çü °ø±â¾ÐÃà ÆßÇÁ
  • ±¸¹è ¾ø´Â ºÎ¹®Çü °ø±â¾ÐÃà ÆßÇÁ
  • ±³Á¤ ±¸¹è°¡ ÀÖ´Â ºÎ¹®Çü °ø±â¾ÐÃà ÆßÇÁ
  • »óºÎ °ø±â¾ÐÃà ½½¸®ºê
  • ÇϺΠ°ø±â¾ÐÃà ½½¸®ºê
  • ¿µ±¸ ÇÏ´ëÁ¤¸Æ ÇÊÅÍ
  • ȸ¼ö °¡´ÉÇÑ ÇÏ´ëÁ¤¸Æ ÇÊÅÍ
  • »öÀüÁ¦°Å dz¼± Ä«Å×ÅÍ
  • °æÇÇÇ÷Àü Á¦°Å ±â±â
  • Ä«Å×ÅÍ À¯µµ Ç÷Àü¿ëÇØ(CDT) ±â±â

Á¤¸ÆÇ÷Àü »öÀüÁõ Ä¡·á ½ÃÀå ±Ô¸ð : ÀûÀÀ Áúȯº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ
  • Æó»öÀüÁõ

Á¤¸ÆÇ÷Àü »öÀüÁõ Ä¡·á ½ÃÀå ±Ô¸ð : ÃÖÁ¾»ç¿ëÀÚº° & CAGR(2025-2032)

  • ½ÃÀå °³¿ä
  • º´¿ø
  • Ä«Å×ÅÍ °Ë»ç½Ç
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ

Á¤¸ÆÇ÷Àü »öÀüÁõ Ä¡·á ½ÃÀå ±Ô¸ð : Áö¿ªº° & CAGR(2025-2032)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´ Áö¿ª
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« Áö¿ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï Á¤º¸

  • »óÀ§ 5»çÀÇ ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
  • ÃÖ±Ù ½ÃÀå µ¿Çâ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ °³¿ä
    • ±â¾÷ÀÇ »ó¼¼
    • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
    • ±â¾÷ÀÇ ºÎ¹®º° Á¡À¯À² ºÐ¼®
    • ¸ÅÃâÀÇ Àü³â´ëºñ ºñ±³(2022-2024)

ÁÖ¿ä ±â¾÷ °³¿ä

  • Johnson & Johnson(USA)
  • Pfizer Inc.(USA)
  • Bayer AG(Germany)
  • Bristol Myers Squibb(USA)
  • Daiichi Sankyo Company, Limited(Japan)
  • Boehringer Ingelheim(Germany)
  • Novartis AG(Switzerland)
  • Aspen Pharmacare Holdings Limited(South Africa)
  • Abbott Laboratories(USA)
  • Medtronic plc(Ireland)
  • Boston Scientific Corporation(USA)
  • Cardinal Health, Inc.(USA)
  • Terumo Corporation(Japan)
  • Cook Medical(USA)
  • Getinge AB(Sweden)
  • Teleflex Incorporated(USA)
  • Smith+Nephew(UK)
  • Baxter International Inc.(USA)
  • Instrumentation Laboratory(USA)

°á·Ð°ú Á¦¾È

KSA 25.04.18

Global Venous Thromboembolism Treatment Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.31 billion in 2024 to USD 3.41 billion by 2032, growing at a CAGR of 5.0% during the forecast period (2025-2032).

The venous thromboembolism (VTE) treatment market plays a crucial role in addressing a significant global health issue marked by blood clot formation in veins, which can lead to serious complications such as pulmonary embolism and deep vein thrombosis. Key drivers of this market include the rising prevalence of VTE linked to sedentary lifestyles, aging populations, and surgical procedures, creating a demand for effective treatments. Advancements in anticoagulant therapies, particularly direct oral anticoagulants (DOACs) and injectable options, have improved treatment outcomes while minimizing bleeding risks. Increased awareness of risk factors and the importance of early diagnosis further bolster market growth. Despite challenges like the need for personalized treatment approaches and patient compliance, the VTE treatment market remains vital in delivering life-saving interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Venous Thromboembolism Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Venous Thromboembolism Treatment Market Segments Analysis

Global Venous Thromboembolism Treatment Market is segmented by Product, Disease Indication, End User and region. Based on Product, the market is segmented into Non-Segmented Pneumatic Compression Pumps, Segmented Pneumatic Compression Pumps without Gradient, Segmented Pneumatic Compression Pumps with Calibrated Gradient, Upper Pneumatic Compression Sleeves, Lower Pneumatic Compression Sleeves, Permanent Inferior Vena Cava Filters, Retrievable Inferior Vena Cava Filters, Embolectomy Balloon Catheters, Percutaneous Thrombectomy Devices and Catheter-Directed Thrombolysis (CDT) Devices. Based on Disease Indication, the market is segmented into Deep Venous Thrombosis and Pulmonary Embolism. Based on End User, the market is segmented into Hospitals, Catheterisation Laboratories and Ambulatory Surgical Centres. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Venous Thromboembolism Treatment Market

The global market for Venous Thromboembolism (VTE) treatment is significantly influenced by the rising prevalence of VTE cases, which is attributed to several factors including aging populations, sedentary lifestyles, and post-surgical complications. As VTE presents serious health challenges, there is an increasing emphasis on its timely detection and effective treatment. This heightened awareness and focus on managing VTE are propelling the growth of the market, as healthcare providers and patients alike prioritize strategies to mitigate the risks associated with this condition. Consequently, investment in innovative treatment options and preventive measures is becoming increasingly vital in addressing this public health concern.

Restraints in the Global Venous Thromboembolism Treatment Market

The Global Venous Thromboembolism (VTE) Treatment market faces a significant restraint due to the complexity and length of treatment regimens required to effectively manage VTE. These intricate protocols can lead to challenges in patient adherence, as the extended duration and demanding nature of the treatments may overwhelm individuals. Consequently, non-compliance can adversely affect the overall outcomes of the treatment, hindering progress and recovery. This issue emphasizes the need for strategies to simplify treatment plans and enhance patient engagement in order to improve therapeutic results and ensure a more effective management of VTE across diverse populations.

Market Trends of the Global Venous Thromboembolism Treatment Market

The Global Venous Thromboembolism (VTE) Treatment market is witnessing a significant trend towards the adoption of Direct Oral Anticoagulants (DOACs), which have gained popularity for their superior efficacy and convenience compared to traditional warfarin. Medications such as apixaban, rivaroxaban, and edoxaban are favored due to their reduced monitoring requirements and ease of use, making them increasingly attractive to both healthcare providers and patients. This paradigm shift is expected to drive market growth, as healthcare systems increasingly recognize the benefits of DOACs, ultimately improving patient outcomes and adherence in VTE management.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Venous Thromboembolism Treatment Market Size by Product & CAGR (2025-2032)

  • Market Overview
  • Non-Segmented Pneumatic Compression Pumps
  • Segmented Pneumatic Compression Pumps without Gradient
  • Segmented Pneumatic Compression Pumps with Calibrated Gradient
  • Upper Pneumatic Compression Sleeves
  • Lower Pneumatic Compression Sleeves
  • Permanent Inferior Vena Cava Filters
  • Retrievable Inferior Vena Cava Filters
  • Embolectomy Balloon Catheters
  • Percutaneous Thrombectomy Devices
  • Catheter-Directed Thrombolysis (CDT) Devices

Global Venous Thromboembolism Treatment Market Size by Disease Indication & CAGR (2025-2032)

  • Market Overview
  • Deep Venous Thrombosis
  • Pulmonary Embolism

Global Venous Thromboembolism Treatment Market Size by End User & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Catheterisation Laboratories
  • Ambulatory Surgical Centres

Global Venous Thromboembolism Treatment Market Size & CAGR (2025-2032)

  • North America (Product, Disease Indication, End User)
    • US
    • Canada
  • Europe (Product, Disease Indication, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Product, Disease Indication, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Product, Disease Indication, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Product, Disease Indication, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Daiichi Sankyo Company, Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boehringer Ingelheim (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aspen Pharmacare Holdings Limited (South Africa)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abbott Laboratories (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Medtronic plc (Ireland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Boston Scientific Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cardinal Health, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Terumo Corporation (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cook Medical (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Getinge AB (Sweden)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Teleflex Incorporated (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Smith+Nephew (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Instrumentation Laboratory (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦